Overview

The Corporation was formed to manage the manufacturing, distribution, sales and marketing of health care products throughout the world. avVaa has obtained from the German inventor the manufacturing, distribution, sales and marketing rights for products that control specific skin disorders, including eczema, psoriasis, acne, dermatitis and other types of skin conditions.

The management team, under the direction of its Chairman and CEO, Jack Farley, has defined and directed the Company’s focus on the natural skin care product line. The direction of the Corporation has been to focus on North and South American opportunities directly relating to its skin care product line, with rapid expansion planned for the rest of the world after initial product launch in the Americas.

The Company has built a medical Research and Development team that is staffed by world- renowned physicians. The Operations Center and Corporate Headquarters of the Company is based in British Columbia, Canada.

---

Investment Highlights

---

Profile

With the U.S. and many other world economies in an economic downturn, there are few industries that for the most part are immune to the uncertainty going on around them, one of them being healthcare and health care products. With an aging population, demand for healthcare workers, facilities and products to make people feel better are in big demand. Since people can't choose when they fall ill, healthcare is seen as a recession proof industry and one that will always be around.

One Company that is poised to help people in need is avVaa World Health Care Products, Inc. (Pink Sheets: AVVH).  The Company is poised to globally market, manufacture and distribute a range of FDA complaint, over-the-counter, steroid-free, natural skin care products which provide relief from the symptoms and reduce recurrences of specific skin disorders, including eczema, psoriasis, dermatitis, acne and other types of skin conditions.

avVaa’s NEUROSKIN Core products are NEUROSKIN Psoriasis Relief, NEUROSKIN Acne Treatment, NEUROSKIN Mild Skin Moisturizer and NEUROSKIN Itch Relief. These products are registered FDA compliant products for over-the-counter pharmaceutical sales and also FDA compliant products for cosmetic skin care sales. These products are ready to manufacture, distribute and market worldwide. Two other products are NEUROSKIN Nail Fit and NEUROSKIN Razor-Rash which are also registered FDA compliant for over-the-counter.

The United States alone has an estimated market size of 40 million skin disease sufferers and a potential market spending of US $4 Billion. US market share projections reflect a 0.02% of total market share in Year 1, increasing to 1.5% in Year 3, producing sales of US $12.8 million and US $59.3 million respectively.

avVaa’s Sales & Marketing Division will concentrate on building a strong brand awareness campaign by 120 second, 60 second, 30 second, 10 second, Direct Response Infomercials, along with media coverage with Steve Allen Media Group. By building a strong brand name of the NEUROSKIN the consumers will drive sales into the various market areas: mainstream retail and specialty merchants, direct consumer; institutional; clinical; private brand and cosmetic companies; and health and natural food stores. The NEUROSKIN Psoriasis Relief will be introduced throughout the United States by a 120 second infomercial and will start airing in September 2009, and by the fall of 2009 avVaa’s Sales & Marketing Division will introduce NEUROSKIN Psoriasis Relief on a Regional basis as part of mainstream OTC products to major drug stores across the United States.

The emotional and social consequences of skin disease are often profound and life altering. "In cases where psoriasis plaques are visible, patients can suffer severe humiliation and depression; some even withdraw from society and become isolated. In one study, 75% of patients reported that psoriasis undermined their confidence. Another study reported that 8% felt their life was not worth living".

The management team of avVaa World Health Care Products is strong in the sales and marketing with strong emphasis in financial accounting, pharmaceutical and banking experience. The medical research team is comprised of world-renowned medical professionals in the fields of dermatology and radiation oncology.

In the latter part of March, 09, the Company announced that they expect over the next 12 months to have potential projected sales of $12.7 Million with a gross profitability of $6.8 Million.  With the Company operating in a virtually recession proof industry, and millions in projected revenues in the next couple of years, we felt avVaa World Health Care Products, Inc. (Pink Sheets: AVVH) was a compelling enough story to share with our readers, and we encourage AllPennyStocks.com readers to continue to watch new developments from the Company as they move forward with their line of FDA complaint, over-the-counter, steroid-free, natural skin care products.

---

Product - NEUROSKIN®

NEUROSKIN Psoriasis Relief, Mild Skin Moisturizer, Acne Treatment and Itch Relief are available over-the-counter and are extremely easy to use, non-toxic products, having no side effects on the human body or the environment. The products do not contain unnatural ingredients such as cortisone, antibiotics and alcohol. The formula is non-greasy, odorless and does not stain clothing, unlike other creams and ointments. Patients have reported noticeable reduction of symptoms after just the first application. NEUROSKIN will replace prescription medication for patients, using expensive therapies and steroids. NEUROSKIN fits with the attitude of the century, which is to go more natural and avoid potentially toxic substances.

NEUROSKIN Psoriasis Relief is a steroid-free, natural therapeutic skin care product which treats the symptoms of skin disease such as psoriasis, eczema, dermatitis and other minor skin irritations. This product is FDA-compliant and DIN approved as an over-the-counter OTC product. avVaa owns the blow-molds for the unique 50 ml bottle which was developed using focus groups from the medical fields.

There is presently no cure for psoriasis and eczema, skin diseases which are chronic and require continuous therapy. Patients are required to seek out products that can relieve and treat the symptoms of itching and redness caused by these skin irritations.

NEUROSKIN Psoriasis Relief is a patented all-natural product containing minerals and oils, in a non-greasy, fast drying formula which cools and sooths irritated skin. The product reduces inflammation, redness and itching and it promotes healing and repair of damaged skin, enhancing its natural texture. NEUROSKIN Psoriasis Relief contains no steroids or toxic chemicals.

Tests in Germany have proven the product to be effective on 995 out of 1000 people (99.5%). The tests indicated and proved NEUROSKIN did not cause any side effects. Unlike many competitors, NEUROSKIN does not contain cortisone, antibiotics, alcohol, steroids or other unnatural ingredients or additives. The formula is non-greasy and odorless, does not stain clothing, and is easy to use.

NEUROSKIN Mild Skin Moisturizer is a natural cosmetic for those with sensitive skin (elderly and babies) NEUROSKIN Mild Skin Moisturizer has had early success in the treatment of radiation and thermal burns. Dr. Alden will be working closely with this product in clinical trials for the specific treatment of burns.

NEUROSKIN Acne Treatment is a cosmetic skin care product, which clears up acne, promoting blood circulation on the affected parts of the skin. Within a few days the inflamed "blackhead" pores open, their contents expel, and then proceed to dry up. This product is FDA-compliant and DIN approved as and over-the-counter OTC product.

NEUROSKIN Itch Relief is a steroid-free, all natural topical analgesic lotion, which relieves the discomfort and stops the itch caused by insect bites, allergies, shingles, minor cuts and other minor skin irritations. This product is FDA-compliant and DIN approved as an over-the-counter OTC product.

Disease Descriptions

Psoriasis is a chronic skin disease marked by periodic flare-ups of sharply defined red patches covered by a silvery, flaky surface.

Eczema (atopic dermatitis) is an allergic skin condition that causes itching, sometimes to an intense degree. Over time, the lesions tend to scale and flake. If bacterial or viral infection is introduced by scratching, the affected lesions will ooze.

Acne is a disorder of the skin’s oil glands that results in plugged pores and outbreaks of lesions commonly called pimples or zits. Acne lesions usually occur on the face, neck, back, chest and shoulders.

Products Tested and FDA Compliant

The avVaa Research and Development team feels that NEUROSKIN core products are the first non-toxic effective treatment to all major skin diseases. The Research and Development team will conduct American clinical trials to support the findings in Germany. The core products are registered FDA compliant and DIN approved as over-the-counter pharmaceuticals as well as cosmetic skin care products.

With successful transfer of FDA, DIN numbers and label parameters, from the Inventor to avVaa World Health Care Products, avVaa now owns the exclusive right to manufacture, market, label, distribute and sell its line of proven skin care products throughout the United States and Canada. avVaa products included in the FDA and DIN transfers are: NEUROSKIN Acne Treatment, an acne medication lotion; NEUROSKIN Psoriasis Relief, for seborrheic dermatitis and psoriasis lotion; and NEUROSKIN Itch Relief, a topical analgesic lotion.

For online purchases, go to www.help4skincare.com.

---

Market Potential

• Seventeen million (17 million) Americans have acne (*The National Institute of Arthritis and Musculoskeletal and Skin Diseases).
• There are 7 million people living in the United States that are affected by some form of psoriasis. Approximately two hundred and fifty thousand new cases are reported each year. (*Well-Connected Report, 1999 Nidus Information Services Inc., June 1999).
• “Skin problems are exceedingly common: 30% of Americans have dermatological conditions requiring a physician's care. Moreover, the skin and its appendages (the hair and nails) play a paramount role in our psychological makeup.” (*Cecil Textbook of Medicine 20th edition, 1996).
• Over 16 million people living in the United States are affected by eczema (*The National Institute of Arthritis and Musculoskeletal and Skin Diseases).
• *Research by the National Psoriasis Association, the USA Dermatologist Association and other institutions indicate that close to $4 billion is spent on treatments for psoriasis, eczema, and acne per year.
• “85% of the US population between ages 12-25 develops some form of acne.” (*FDA Consumer Report, “On the Teen Scene” section of WebMD Health). The psoriasis market is continuing to grow with the aging population and affects between 0.5% - 3% of the world's population, (*Well-Connected Report, 1999 Nidus Information Services Inc., June 1999).
• *Forrester Research states in their article “B2B Healthcare Spending Shifting Online” (Jan. 2000), “Over-the-counter drugs, health and beauty aids will contribute $1.9 billion and $900 million, respectively, to the online retail category.”
• The market size for the health and natural food store market tops 9,245 stores in USA with sales reaching $14 billion in 2000. (*source: www.marketresearch.com)

---

Target Markets

Primary Target Markets

• Individuals suffering with psoriasis, eczema and acne and various other skin diseases;
• Pharmaceutical Retail outlets;
• Mainstream and Specialty Drug and Food Chain outlets; and
• Institutions – hospitals, clinics, prisons.

Secondary Target Markets

• Health and Natural Food Store Market.
• Private brand companies.

The initial focus will be directed on the primary US target markets. Entry into Canada, the rest of the North America, Central America, South America and eventual world markets will be quickly executed. Distribution and sales agreements have been discussed with several countries to date.

Private branding allows skin care companies such as Avon, Mary Kay, Revlon, etc. to market avVaa products under their specific brand name. NEUROSKIN is registered as FDA compliant, both as a skin care cosmetic and over-the-counter pharmaceutical product, the market appeal for private branding and cosmetic companies is very strong.

Recent News and Press Releases

avVaa World Health Care Products, Inc. Announces the completion of its first week of DRTV 120/60 second test commercials for Neuroskin(R) Psoriasis Relief
PR Newswire (Tue, Sep 1)

avVaa World Health Care Products, Inc. Launches DRTV-Direct Response Television Campaign for Neuroskin(R) Psoriasis Relief To Over 450 Million Potential Subscribers Spanning 7 Cable Networks
PR Newswire (Tue, Aug 25)

avVaa World Health Care Products, Inc. Launches MyNeuroskin.com Internet Marketing Campaign
PR Newswire (Fri, Aug 21)

avVaa World Health Care Products, Inc. Announces DRTV-Direct Response Television Media Buying Campaign for Neuroskin(R) Psoriasis Relief Test Week With 46 Spots
PR Newswire (Thu, Aug 20)

avVaa World Health Care Products, Inc. DRTV Campaign for Neuroskin(R) Psoriasis Relief Is on Schedule for August Launch
Marketwire (Wed, Aug 12)

avVaa World Health Care Products Inc. Announces Web Site Design for Neuroskin(R) Psoriasis Relief DRTV Campaign
PR Newswire (Thu, Jul 16)

avVaa World Health Care Products, Inc. Announces That Its DRTV Commercial for Neuroskin(R) Psoriasis Relief Is In Final Stages Of Completion
PR Newswire (Wed, Jul 8)

avVaa World Health Care Products, Inc. Signs Agreement with 3PL Worldwide, Inc., for Order Management & Fulfillment for avVaa's Product
PR Newswire (Mon, Jul 6)

avVaa World Health Care Products, Inc. Announces Engagement of Koeppel Direct for their DRTV-Direct Response Television Media Buying Campaign
PR Newswire (Thu, Jul 2)

avVaa World Health Care Products, Inc. Announces That The Company Has Moved Ahead With Filming Their DRTV Commercial
PR Newswire (Wed, Jul 1)
 

---

Management

Jack Farley
C.E.O. / Chairman of the Board & Founder

Jack is distinguished as a 32-year veteran of Petro-Canada Marketing, a major international petroleum corporation. He brings extensive experience in planning, distribution, marketing, retailing, merchandising and contract negotiations. Jack retired from Petro-Canada in 1994. Jack spent two years as a sales and marketing consultant to Conoco Oil in the USA in 1995 and 1996. Jack has worked on the avVaa project for nine years and has developed a close relationship with the inventor, and Dr. Mark Alden. When time permits, Jack enjoys working with his champion Labrador Retrievers as well as fishing and the outdoors at his rustic Babine Lake cabin in beautiful central British Columbia.

Lorie Campbell-Farley
President/COO
Founder of avVaa World Health Care/Advisor to Board

Lorie contributes over 25 years of management, sales, and marketing experience. Previously, Lorie was supervisor of 13 retail outlets for a major fashion store. In addition, Lorie has owned and operated a consulting business in the trade show booth industry which included concepts and designs to corporation's across Canada. Lorie heads avVaa's new business development, design, and packaging for the company's extensive animal care product line. In the past, Lorie was an accomplished equestrian rider who now owns a beautiful gelding registered paint horse: "BC Absolutlee Macho (Arnold)". Arnold is an APHA Halter Honour Roll Gelding, APHA Champion in both Amateur & Open, APHA Superiors in Hunter under Saddle & Halter and many High Point awards. Lorie and her horse enjoy life while competing in the APHA shows in British Columbia and Alberta. In her spare time, Lorie is also a dedicated breeder of CKC (Canadian Kennel Club) Registered Labrador Retrievers with accomplishments in show, field and obedience championships. Lorie uniquely combines her business background with animal care expertise.

Ruth Brennan
Controller/Consultant

Ruth completed several different sales and marketing courses as well as business management courses during her career. With her steady mind and calm overview, it was a natural progression for Ruth to take on the challenge of General Manager and Controller with a manufacturing company. Changing priorities led her to establish her own accounting and consulting business several years ago. She has now joined avVaa, as a consultant.

Stephanie Tambellini
Graphic Design & Merchandising/Consultant

Stephanie has over 15 years of extensive experience in all aspects of creative marketing including: graphic design, word mark creation, concept creation and development, market research, program management and product production. She has developed the avVaa brand and will continue to create stunning designs to showcase these products to the world.

Dr. Jerry A Moore, PhD, J.D.
avVaa Science and Regularity Consultant

Dr. Moore brings a broad base of scientific and business expertise that avVaa will be able to capitalize upon immediately. He will direct new product introductions to compliment the existing avVaa products and the regulatory affairs from a manufacturing perspective as well as insuring the avVaa product offerings are regulatory compliant with either the US Food and Drug Administration (FDA) or US Environmental Protection.

Prior to joining avVaa World Health Care Products Inc., as Chief Science and Regulatory and Advisor to the Board, Dr. Moore’s Federal Service career spanned 25 years between the United States Department of Agriculture (USDA), Agriculture Research Services (ARS) and the United States Environmental Protection Agency (EPA) created by President Nixon in 1970. Dr. Moore is a Charter Member of the EPA . Dr. Moore earned one gold medal, three silver medals, and 10 bronze medals during his distinguished career at the EPA and received the coveted “Thousand Points of Light Award” from President George Bush at the White House in 1984. Dr. Moore is a Charter Member of the Wildlife Society and the American Forestry Association
 

---

Contact

avVaa World Health Care Products, Inc.

Jack Farley, C.E.O. / Board Chairman
Phone: 888.547.2294
Email: jfarley@avvaa.com

OR

Lorie Campbell-Farley, President/COO
Email: lcfarley@avvaa.com

---

FORWARD LOOKING STATEMENTS

This report includes forward-looking statements that reflect avVaa World Health Care Products, Inc. current expectations about its future results, performance, prospects and opportunities. avVaa World Health Care Products, Inc. has tried to identify these forward-looking statements by using words and phrases such as "may," "will," "expects," "anticipates," "believes," "intends," "estimates," "plan," "should," "typical," "preliminary," "we are confident" or similar expressions. These forward-looking statements are based on information currently available and are subject to a number of risks, uncertainties and other factors that could cause avVaa World Health Care Products, Inc.'s actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. These risks, uncertainties and other factors include, without limitation, the Company's growth expectations and ongoing funding requirements, and specifically, the Company's growth prospects with scalable customers, and those outlined above. Other risks include the Company's limited operating history, the Company's history of operating losses, consumers' acceptance, the Company's use of licensed technologies, risk of increased competition, the potential need for additional financing, the terms and conditions of any financing that is consummated, the limited trading market for the Company's securities, the possible volatility of the Company's stock price, the concentration of ownership, and the potential fluctuation in the Company's operating results.

---

Disclaimer

AllPennyStocks.com feature stock reports are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this report was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. For more information see our disclaimer section, a link of which can be found on our web site. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. This is an advertisement for avVaa World Health Care Products, Inc. The purpose of this advertisement, like any advertising, is to provide coverage and awareness for the company. The information provided in this advertisement is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.

© 1999-2009 AllPennyStocks.com. All rights reserved. AllPennyStocks.com is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. AllPennyStocks.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), AllPennyStocks.com will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the AllPennyStocks.com web site. AllPennyStocks.com has been compensated sixty eight Million rule-144 shares by the company for its efforts in presenting the AVVH profile on its web site and distributing it to its database of subscribers as well as other services. AllPennyStocks.com may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report. As of the profile date, no shares have been sold. Information presented on our web site and within our reports contain "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “expects’”, “will,” “anticipates,” “estimates, “believes,” or that by statements indicating certain actions “may,” “could,” or “might” occur.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.